Please assess the completion status of the following clinical trial:

Trial Title: Thoracal Radiotherapy and Tarceva

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>18 years~* Histological or cytological verified NSCLC~* Palliative radiotherapy to thorax indicated~* ECOG Performance status 0-2~* Fertile patients must use contraception~* Signed informed consent~* Ability to understand and fill in QoL questionnaires~* Capability to take per os medication~* Serum bilirubin \< 2 times upper limit of normal (ULN)~* AST and ALT \< 2 times ULN (\< 5 times ULN if liver metastases are present)~* Creatinine \< 5 times ULN~Exclusion Criteria:~* Pregnancy or nursing~* Other prior or concurrent malignant disease likely to interfere with study treatment or comparisons~* No evidence of other significant laboratory finding or concurrent uncontrolled medical illness, that in the opinion of the investigator, would interfere with study treatment or results comparison or render the patient at high risk for treatment complications~* No prior radiotherapy to the same organ / place~* No concurrent treatment with other experimental drugs~* Known brain metastases in need of radiotherapy~* Known hypersensitivity to erlotinib or other substances in the erlotinib tablets.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Radiotherapy combined with erlotinib (Type: EXPERIMENTAL): Standard treatment 3 Gy x 10 to lung tumor and mediastinal lymph nodes and erlotinib given concomitantly, 150 mg p.o. daily from the day before radiation, until the last day of radiation.
- Radiotherapy alone (Type: ACTIVE_COMPARATOR): Radiotherapy 3 Gy x 10 alone

Based on this trial design, predict the completion outcome and termination type (if applicable).